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Abstract: Cellular communication plays a critical role in diverse aspects of tumorigenesis including
tumor cell growth/death, adhesion/detachment, migration/invasion, angiogenesis, and metastasis.
G protein-coupled receptors (GPCRs) which constitute the largest group of cell surface receptors
are known to play fundamental roles in all these processes. When considering the importance of
GPCRs in tumorigenesis, the adhesion GPCRs (aGPCRs) are unique due to their hybrid structural
organization of a long extracellular cell-adhesive domain and a seven-transmembrane signaling
domain. Indeed, aGPCRs have been increasingly shown to be associated with tumor development
by participating in tumor cell interaction and signaling. ADGRG1/GPR56, a representative tumor-
associated aGPCR, is recognized as a potential biomarker/prognostic factor of specific cancer types
with both tumor-suppressive and tumor-promoting functions. We summarize herein the latest
findings of the role of ADGRG1/GPR56 in tumor progression.
Keywords: adhesion GPCR; GPR56; ligand; signaling; tumorigenesis
1. Introduction
G protein-coupled receptors (GPCRs) play a central role in cellular communication [1–3].
Aberrant expression and/or genetic mutations of GPCRs are often identified in various
cancer types, manifesting either tumor-promoting or tumor-suppressive functions [4–6].
Furthermore, GPCR transactivation of different signaling molecules such as the receptor
tyrosine kinases (RTKs) are closely linked to tumorigenesis [7,8]. Therefore, GPCRs and
their cognate ligands as well as the specific signaling networks induced by the GPCR-ligand
interaction are the key areas of interest for cancer research.
In recent years, the GPCR superfamily has been further classified based upon their
phylogenetic characteristics and subdivided into five main families, including glutamate,
rhodopsin, adhesion, frizzled/Taste2, and secretin (GRAFS) [9]. Among these, the adhesion
GPCRs (aGPCRs) have several unusual structural and functional features [10] (Figure 1).
Firstly, the extracellular region (ECR) of most aGPCRs is uncommonly large and often
consists of diverse cell-adhesive protein modules such as the epidermal growth factor
(EGF)-like, immunoglobulin (Ig)-like, and lectin-like domains at its N-terminal half. These
protein modules normally function as the binding sites for specific cellular ligands and/or
binding partners of aGPCRs [10,11]. Secondly, the majority of aGPCRs comprise a signature
GPCR autoproteolysis-inducing (GAIN) domain at the C-terminal half of ECR. A self-
catalytic proteolytic reaction normally occurs during receptor biosynthesis at the consensus
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GPCR proteolysis site (GPS) within the GAIN domain [12–14]. As a result, GPS cleavage
disjoints the receptor into a non-covalent dual-subunit complex comprising an N-terminal
extracellular fragment (NTF) and a C-terminal 7TM fragment (CTF) [12–14] (Figure 1A).
Thirdly, the activation and signaling mechanisms of aGPCRs are multifaceted, including the
GPS cleavage-dependent and -independent as well as NTF-CTF dissociation-dependent
and -independent modes [10,15–17]. Nevertheless, a tethered agonism model is well
accepted as the common activation mechanism for most aGPCRs [18,19]. This involves
the unmasking and binding of a tethered agonistic Stachel peptide with its own 7TM,
following the separation of NTF from CTF caused by the binding of its cellular ligand(s) to
the ECR [20] (Figure 1B).
Cells 2021, 10, x FOR PEER REVIEW 2 of 17 
 
 
catalytic proteolytic reaction normally occurs during receptor biosynthesis at the consen-
sus GPCR proteolysis site (GPS) within the GAIN domain [12–14]. As a result, GPS cleav-
age disjoints the receptor into a non-covalent dual-subunit complex comprising an N-ter-
minal extracellular fragment (NTF) and a C-terminal 7TM fragment (CTF) [12–14] (Figure 
1A). Thirdly, the activation and signaling mechanisms of aGPCRs are multifaceted, in-
cluding the GPS cleavage-dependent and -independent as well as NTF-CTF dissociation-
dependent and -independent modes [10,15–17]. Nevertheless, a tethered agonism model 
is well accepted as the common activation mechanism for most aGPCRs [18,19]. This in-
volves the unmasking and binding of a tethered agonistic Stachel peptide with its own 
7TM, following the separation of NTF from CTF caused by the binding of its cellular lig-
and(s) to the ECR [20] (Figure 1B). 
Due to the structural complexity and functional diversity, the study of aGPCRs is still 
in its infancy. The hu an aGPCR family consists of 33 distinct members, some of which 
have been increasingly linked to various aspects of cancer biology [21–23]. In this review 
article, we summarize the molecular and functional properties of ADGRG1/GPR56 and 
discuss its diverse roles in tumor progression. 
 
Figure 1. Structural features and activation mechanisms of adhesion GPCRs. (A) Schematic depict-
ing the structural organization of aGPCRs in general. The ECR contains multiple cell-adhesive pro-
tein domains (indicated by different colored lines and shapes) followed by a GAIN domain. The 
Stachel peptide is depicted as a brown cylinder. ECR, extracellular region; CTF, C-terminal fragment; 
NTF, N-terminal fragment; GAIN, GPCR autoproteolysis-inducing. Illustration was generated us-
ing the Biorender software. (B) The diverse potential activation mechanisms mediated by aGPCRs. 
2. Overview of the ADGRG1/GPR56 Receptor 
2.1. Structural Characteristics of the ADGRG1/GPR56 Protein 
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coded by the ADGRG1 gene on the chromosome 16q21 [24]. However, extensive RNA 
splicing of its transcripts is predicted to generate at least five different GPR56 protein 
isoforms that are different in the composition of ECR and/or the first intracellular loop. 
These GPR56 receptor variants have been found to have differential functional and sig-
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Figure 1. Structural features and activation echanis s of adhesion GPCRs. (A) Schematic depicting
the structural organization of aGPCRs in general. The ECR contains multiple cell-adhesive protein
domains (indicated by different colored lines and shapes) followed by a GAIN domain. The Stachel
peptide is depicted as a brown cylinder. ECR, extracellular region; CTF, C-terminal fragment; NTF,
N-terminal fragment; GAIN, GPCR autoproteolysis-inducing. Illustration was generated using the
Biorender software. (B) The diverse potential activation mechanisms mediated by aGPCRs.
Due to the structural complexity and functional diversity, the study of aGPCRs is still
in its infancy. The human aGPCR family consists of 33 distinct members, some of which
have been increasingly linked to various aspects of cancer biology [21–23]. In this review
article, we summarize the molecular and functional properties of ADGRG1/GPR56 and
discuss its diverse roles in tumor progression.
2. Overview of the ADGRG1/GPR56 Receptor
2.1. Structural Characteristics of the ADGRG1/GPR56 Protein
The full-length human ADGRG1/GPR56 receptor is a protein of 693 amino acids
encoded by the ADGRG1 gene on the chromosome 16q21 [24]. However, extensive RNA
splicing of its transcripts is predicted to generate at least five different GPR56 protein iso-
forms that are different in the composition of ECR and/or the first intracellular loop. These
GPR56 receptor variants have been found to have differential functional and signaling
characteristics and are discussed later [25,26]. Moreover, the usage of multiple alternative
transcription start sites has been identified to generate many more diverse GPR56 transcript
variants; however, the frequencies of these transcripts and the resulting protein isoforms
remain to be fully investigated [27,28].
The GPR56 protein consists of a N-terminal PLL (pentraxin/laminin/neurexin sex-
hormone-binding globulin-like) domain and a C-terminal GAIN domain in its ECR
(Figure 2A) [26]. Of interest, the PLL domain shares only a relatively weak homology
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with either the pentraxin or laminin/neurexin/sex-hormone-binding globulin domain
hence is a rather novel structural module unique to GPR56 [26]. The GPR56-GAIN domain
is unusually small in comparison to those of other aGPCRs. Indeed, its GAIN sub-domain
A contains only three α-helices compared to the six α-helices identified in the canonical GAIN
sub-domain A of ADGRL1/Latrophilin-1 and ADGRB3/BAI-3 [13,26,29]. Nevertheless, the
GAIN sub-domain B of GPR56 seems to be comparable with those of other aGPCRs by
having 13 β-strands and 2 small α-helices. The proteolytic cleavage of GPR56 takes place
between Leu382 and Thr383 at the consensus GPS motif located between the 12th and 13th
β-strands of the GAIN sub-domain B [26]. Interestingly, the PLL domain is absent in two
alternatively-spliced GPR56 isoforms, while the other three GPR56 variants contain essentially
the same full-length ECR [25]. Altogether, GPR56 is a fully-processed archetypal aGPCR
consisting of non-covalently associated NTF-CTF receptor subunits (Figure 2B).
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2.2. Ligands/Binding Partners of the ADGRG1/GPR56 Protein
In terms of specific cellular ligands/binding partners, GPR56 was one of the first
aGPCRs to be deorphanized (Figure 2B). Little et al. showed that the CD9 and CD81
tetraspanins form a complex specifically with GPR56 and many G protein subunits, includ-
ing Gαq, Gα11, and Gβ [30]. This GPR56-tetraspanin-G protein complex was important for
subsequent signaling regulation, hence suggesting a regulatory role for CD9 and CD81 as
the membrane scaffolding proteins of GPR56. Xu and colleagues identified tissue transglu-
taminase (also named TG2) as the specific extracellular matrix (ECM) ligand of melanoma
cells [31]. Critically, it was found that the TG2-GPR56 interaction inhibited the growth and
metastasis of melanoma tumors [32–34]. Piao’s group subsequently discovered another
ECM ligand of GPR56, the type III collagen (collagen-III), in the mouse brain [35]. The
interaction of collagen-III and GPR56 activated the Gα12/13-RhoA signaling pathway and
played an essential role in the proper lamination of the cerebral cortex in the developing
brain. Later studies by the same group also identified a different ECM ligand, laminin,
for GPR56 [36]. It was revealed that the GPR56 receptor in oligodendrocyte precursor
cells (OPCs) responded to the microglia-derived TG2 in the presence of laminin. Recently,
the PLL domain was identified as the specific binding site for collagen-III and TG2 on
GPR56 [37,38].
As well as protein ligands, heparin was recently identified by Chiang et al. as a novel
glycosaminoglycan (GAG) binding partner of GPR56 [39]. Interestingly, heparin-GPR56
interaction reduced the shedding of its NTF and enhanced cell adhesion and motility [39].
Jin et al. demonstrated that progastrin, an 80 aa-long precursor of the peptide hormone
gastrin, bound directly to GPR56 expressed in colonic stem/progenitor cells and colon
cancer cells to promote cellular proliferation [40]. More recently, Chen and colleagues
screened a large number of bioactive metabolites from intestinal microbiota and identified
the essential amino acid L-Phe, found abundantly in the culture supernatants of the species
B. theta (B. theta C34), as a small molecule agonist of GPR56 and ADGRG3/GPR97 [41].
Functional analyses showed that the ECR of GPR56 was required for the receptor activation
induced by L-Phe. Nevertheless, GPR56 activation by L-Phe required very high concen-
trations of L-Phe (>1 mM); hence, the physiological significance of this ligand-receptor
interaction remained unanswered. Lastly, Li et al. identified phosphatidylserine (PS) as
an isoform-specific ligand of the GPR56-S4 variant restrictedly expressed in microglial
cells [42]. The GPR56-S4 isoform lacked the entire PLL domain, but the specific PS-S4
isoform interaction was shown to be critical for microglia-mediated synaptic pruning
during brain development [42].
Finally, receptor-specific monoclonal antibodies (mAbs), polyclonal antibodies (pAbs),
and monobodies have been generated to serve as the artificial ligands of GPR56 for various
functional studies [43–47]. Moreover, 3-α-acetoxydihydrodeoxygedunin (3-α-DOG) and
dihydromunduletone (DHM) were identified as a selective small chemical agonist and
antagonist of GPR56, respectively [48–50].
2.3. Activation and Signaling Mechanisms of ADGRG1/GPR56
Diverse activation mechanisms of the GPR56 receptor, including the GAIN domain-
dependent/-independent and GPS cleavage-dependent/-independent modes, have been
identified (Figure 2C) [18,47,51,52]. However, increasing evidence suggests an unusual
signaling transduction mechanism in which the GPR56-NTF acts as a repressor of the
basal GPR56 signaling. Indeed, NTF-truncated GPR56 receptors are constitutively active
displaying increased SRF and NFAT activities, TGF-α shedding, β-arrestin binding, and
receptor ubiquitination when expressed in transfected cells [51,52]. Likewise, deletion
of the PLL domain increases the signaling activity of GPR56 [26]. These results strongly
suggest that the activation of GPR56 (and likely most other aGPCRs) is mostly mediated
via the dissociation/conformational change of the NTF. This permits a newly exposed
tethered-agonist peptide within the CTF known as the Stachel sequence to self-activate
receptor signaling [18,19].
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As such, in comparison to the wild-type (WT) GPR56-CTF, CTF variants of GPR56
with truncated N-terminal regions showed reduced abilities to activate the Gα13 protein
and the serum response element (SRE)-luciferase activity in transfected cells. On the other
hand, synthetic peptides of the β-strand 13 of GPR56 GAIN sub-domain B were sufficient to
induce the signaling activity of GPR56 [18]. Therefore, it was established that following the
dissociation of NTF, the Stachel peptide of GPR56-CTF was exposed to interact with its own
7TM moiety, leading to conformational changes and activation of the receptor. Most recent
studies have further substantiated this novel activation mechanism by demonstrating that
binding of cognate ligands such as collagen-III and activating mAbs elicit GPR56 activation
and Gα12/13-RhoA signaling after the ligand-induced NTF-CTF dissociation [44,48,53].
Recently, it was shown that the GPR56 receptor still remains constitutively active
after the removal of its entire ECR. Nevertheless, this ECR-less GPR56 receptor variant
only activated NFAT and induced TGF-α shedding, but not the SRF activity. This finding
thus suggested a GAIN domain-independent mechanism of GPR56 activation [51,54]. On
the other hand, 3-α-DOG was able to activate the GPS cleavage-deficient GPR56-F385A
mutant [48,50]. Likewise, several GPR56-specific monobodies were found to activate the
same GPR56-F385A mutant efficiently [47]. These results indicated that these specific
agonists bind to the ECR of GPR56 and cause a unique conformational change that activates
the receptor without the need of its proteolytic modification, hence supporting the GPS
cleavage-independent activation mechanism of GPR56 [55].
Similar to the various GPR56 activation mechanisms described above, diverse GPR56-
mediated signaling pathways were reported. Notably, most of the GPR56 signaling stud-
ies have shown the specific involvement of the Gα12/13-RhoA signaling axis as men-
tioned previously [56]. Nevertheless, additional signaling pathways involving Gαi, Gαq,
Gβγ, β-arrestin, mTOR, PKCα, NF-κb, and Src-Fak have also been described elsewhere
(Figure 2C) [30,32,52,57–59]. In conclusion, multiple activation and signaling pathways of
GPR56 have been identified that seem to depend mainly on the specific ligands and cell
types studied.
2.4. The Biological Functions of GPR56
Due to its broad mRNA expression patterns in the brain, kidney, testis, thyroid, pan-
creas, skeletal muscle and the hematopoietic system (BioGPS.org), GPR56 is a functionally
versatile aGPCR involved in many physiological processes. In brief, the highest GPR56
expression level was detected in CD56+ NK cells, although cytotoxic CD8+, CD4+, and γδ
T lymphocytes also expressed significant levels of GPR56 [60,61]. In the nervous systems,
GPR56 expression was detected in Cajal–Retzius cells, radial glial cells, Tuj1+ migrating
neurons, OPCs, Schwann cells (SCs), and microglial cells [35,36,62–65]. GPR56 was identi-
fied as the most abundantly expressed GPCR in the pancreatic islets, especially β-cells [66].
GPR56 was expressed in mouse Sertoli cells as well as Mullerian duct epithelium of avian
female gonads [67,68]. For the general review of the role of GPR56 in health and disease,
the readers are referred to a recent review article [69].
As the single disease gene responsible for bilateral frontoparietal polymicrogyria
(BFPP), GPR56 is undoubtedly best known for its essential role in normal cerebral cortical
development [24,35]. Subsequent studies showed that GPR56 is also critically involved
in the neuronal myelination of the CNS and peripheral nervous system (PNS), myelin
repair in CNS neurons, the proliferation of OPCs, proper radial axonal sorting by SCs,
microglia-mediated synaptic pruning, and antidepressant response [36,62–64,70,71].
In addition to the nervous systems, GPR56 has been shown to play a regulatory
role in myoblast fusion and mechanical overload-induced muscle hypertrophy, NK cell
cytotoxic activity, hemostatic shear-force sensing by platelets, pancreatic islet function,
the development and differentiation of hematopoietic stem/progenitor cell, male gonad
development in mice, as well as the normal development of avian embryonic Müllerian
duct [43,59,66–68,72–79].
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Importantly, GPR56 was often detected and implicated in the development of many dif-
ferent types of cancers, including melanoma, breast, non-small cell lung, esophageal squa-
mous cell cancer [80], ovarian, colon, pancreatic carcinoma [81,82], glioblastoma/astrocyto
ma [83], and leukemia [79,84,85]. In general, GPR56 was shown to regulate cell growth,
adhesion, and migration of diverse cancer cell types. In addition, a role for GPR56
in modulating the epithelial-mesenchymal transition (EMT), angiogenesis, and chemo-
/radioresistance of cancer cells has been reported (Figure 2D). Overall, increasing evidence
has indicated that GPR56 might function as the biomarker/prognostic factor of certain
cancers and a potential tumor-promoter or tumor-suppressor for others.
3. ADGRG1/GPR56 as a Cancer Marker and/or Prognostic Factor
Due to its restricted expression in certain stages of tumor development or the associ-
ation of its expression levels with the metastatic stage or survival rate of cancer patients,
GPR56 was thought to act as a potential biomarker and/or prognostic factor of certain
cancers. Identified independently by Liu et al. and Zendman et al. in 1999, GPR56 (also
named TM7XN1) transcripts were found to be expressed differentially in human melanoma
cell lines [86,87]. Notably, GPR56 was strongly expressed in less metastatic melanoma cells,
while markedly reduced in the highly metastatic ones. Therefore, the expression levels of
GPR56 transcripts seemed to correlate inversely to the metastatic potentials of melanoma
cells. Subsequent studies indeed showed a similar contrary relationship between GPR56
protein expression and tumor metastasis of the melanoma lesions [31–33]. Nevertheless,
more studies are needed to fully verify the potential role of GPR56 as a negative metastatic
marker of human melanoma cells.
Saito et al. found that GPR56 expression was positively regulated by the ecotropic
viral integration site-1 (EVI1) transcription factor in acute myeloid leukemia (AML) cells.
As such, GPR56 was highly expressed in EVI1high AML cells that displayed strong cell
adhesion and antiapoptotic activities [79]. GPR56 gene silencing in AML cells resulted
in reduced cell growth and increased apoptosis. In addition, Gpr56 was shown to be
involved in the normal development and repopulating ability of HSCs in mice. As EVI1
was implicated in regulating the stemness of leukemia cells, GPR56 was suggested as a
potential therapeutic target for EVI1high AML [79].
Consistent with this, Pabst et al. later identified GPR56 as a reliable leukemia stem cell
(LSC) biomarker for most primary human AMLs by using next-generation sequencing and
in vivo analyses of LSC frequencies. Moreover, the GPR56 expression level in LSCs was
positively correlated with high-risk AML groups and poor clinical outcomes [85]. Daga et al.
subsequently showed that GPR56 is the prominent surface marker of the LSC-enriched
CD34+CD38− AML cells, while Daria et al. confirmed the association of high GPR56
expression with the inferior prognosis of AMLs [88]. Experiments involving the adoptive
transfer of GPR56-expressing cells significantly promote leukemia development and reduce
survival rate in mice. In addition, the inhibition of AML cell engraftment by GPR56-specific
Abs further supports a causal link between GPR56 and cancer progression [79,84,85]. In
conclusion, GPR56 not only is a valid LSC marker and a disadvantageous prognostic factor
of AML but also a potential anti-leukemic therapeutic target.
Liu et al. showed that GPR56 is an independent unfavorable prognostic factor of
epithelial ovarian cancer (EOC) by investigating its immunohistochemistry expression in
110 ovarian serous carcinoma samples. They found that the GPR56 expression level was
significantly associated with the advanced FIGO (International Federation of Gynecology
and Obstetrics) stage and positive lymph node invasion of EOC [82]. Likewise, Lim
et al. examined GPR56 expression levels in the tissue samples of colorectal cancer (CRC)
patients by immunohistochemistry and found that the GPR56high expression group had a
lower 5-year overall survival rate than the GPR56low expression group, suggesting that the
GPR56 expression level might be a prognostic indicator of CRC [89]. Zhang et al. further
demonstrated that GPR56 is involved in modulating the plasticity of cancer stem cells
(CSC) of CRC to a more drug-resistant phenotype. It was believed that GPR56 promoted
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drug resistance of CRC by upregulating multidrug resistance protein 1 (MDR1) expression
via a RhoA-dependent signaling pathway [90] (Table 1).
Table 1. ADGRG1/GPR56 as a cancer marker and/or prognostic factor.
Cancer Type Function References
Melanoma Potential negative metastaticmarker/factor [31–33,86]
Acute myeloid leukemia Leukemia stem cell markerUnfavorable prognostic factor [79,84,85,88]
Epithelial ovarian cancer Unfavorable prognostic indicator [82]
Colorectal cancer Unfavorable prognostic indicatorPromote drug-resistant cancer stem cell [89,90]
While the role of GPR56 as unique marker and/or prognostic factor of certain cancer
types was strongly implicated, several caveats need to be considered. For example, a
systematic evaluation of GPR56 protein expression in human cancer cells and tissues is yet
to be conducted. As the splice variants and protein isoforms of GPR56 are not examined
in most cancer studies, the possible impact of these receptor variants in the progression
of different tumors remains obscure. Thus, the exact GPR56 RNA transcript and protein
variants in different stages of tumor development need to be investigated fully. The results
of these studies shall provide better insights into the understanding of the role of GPR56 as
unique marker/prognostic factor of certain malignancy.
4. The Tumor-Suppressive Role of ADGRG1/GPR56
As mentioned above, the expression levels of GPR56 transcripts were found to corre-
late inversely to the metastatic potentials of human melanoma cell lines, thus suggesting a
possible suppressive role for GPR56 in melanoma metastasis. The following studies, mainly
conducted by Xu’s group, have shown that the interaction of GPR56 and its ECM ligand,
TG2, inhibited the growth, angiogenesis, and metastasis of melanoma cells in vivo [31–33].
Specifically, the secretion of vascular endothelial growth factor (VEGF) was inhibited as a
result of GPR56-TG2 interaction, thereby reducing the blood vessel formation at the tumor
xenografts [32]. It was further shown that a serine threonine proline-rich (STP) segment
of the GPR56-NTF mediated its interaction with TG2 specifically and deletion of the STP
segment lead to GPR56 activation via a protein kinase C (PKC) α-dependent pathway to
promote VEGF production and tumor angiogenesis [32].
The authors subsequently further uncovered a novel antagonistic relationship between
GPR56 and TG2 during melanoma progression. Thus, the ECM cross-linking enzyme TG2
was shown to promote melanoma growth due to its enzyme activity, but this tumor-
promoting effect was antagonized by GPR56-mediated internalization and degradation
of TG2 [33]. The GPR56-modulated TG2 degradation resulted in the reduced deposition
of fibronectin, a major ECM protein, and focal adhesion kinase (FAK), leading to changed
ECM compositions and cell-ECM adhesion in tumor tissue microenvironments [33]. It
was believed that the modified ECM in part obstructed melanoma metastases and expan-
sion. Altogether, these results point to an inhibitory role for GPR56 in the progression
of melanoma lesions. Contrarily, our recent data on the cellular functions of GPR56 in
human melanoma cell lines has shown that activation of GPR56 receptor by an immobilized
agonistic mAb promoted cell migration and invasion via the production of inflammatory
cytokine, IL-6 [44]. These discrepancies may be due to the use of different melanoma
cell lines and experimental set-ups, distinct fates of the receptor subunits and differential
receptor signaling activities induced by different ligands/binding partners. Therefore, the
tumorigenic role of GPR56 during melanoma development requires further investigation.
Shashidhar et al. discovered that GPR56 was highly expressed in glioblastoma multi-
forme/astrocytoma tumors [83]. In addition, co-localization of GPR56 and α-actinin was
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detected on the leading edges of the glioblastoma cell membranes. Cellular adhesion was
inhibited upon cultured with immobilized recombinant GPR56-ECR, resulting in unusual
cytoskeletal organization and cell rounding, suggesting a role for GPR56 in cellular ad-
hesion and migration. Ohta et al. developed agonistic Abs specific to GPR56-ECR and
showed that GPR56 activation in the U87-MG human glioma cell line by these agonistic
Abs lead to retarded cell migration via a Gαq-Rho signaling pathway [45].
More recently, Moreno et al. reported that GPR56 played a restrictive role in the
mesenchymal differentiation and radioresistance of glioblastoma (GBM) cells [57]. Based
on the gene expression and epigenetic profiles, a total of five different subtypes of adult
GBM were classified including the glioma-CpG island methylator phenotype (G-CIMP),
proneural, neural, classical, and mesenchymal [91–93]. In general, the poorest prognosis
was found in patients of the non G-CIMP GBM subtypes, while the G-CIMP GBM patients
usually showed a more favorable prognosis [91]. It was well known that the non-G-CIMP
GBMs can transform intrinsically from one subtype to another, and the mesenchymal
subtype was correlated more strongly with higher radioresistance and shorter survival
prognosis [94,95]. Of importance, a mesenchymal transition of GBMs also occurred in
response to therapy.
GPR56 was found to be strongly expressed in proneural and classical GBM cells, but
its expression was greatly reduced, even lost, during the transition of these cells toward
a mesenchymal phenotype. Moreover, in vitro and in vivo mesenchymal differentiation
and radioresistance were enhanced in GPR56-knockdown glioma-initiating cells [57]. As
a result, a low GPR56-associated transcriptomic signature was associated with a poor
outcome in GBM patients. It was shown that GPR56 might impede mesenchymal differ-
entiation and radioresistance in part via the inhibition of the NF-κB signaling pathway in
GBM cells. Finally, a positive correlation was identified between a low GPR56-associated
signature and the mesenchymal phenotype-related signatures and inflammatory signatures
of multiple tumor types in addition to GBMs. Conversely, a negative correlation was noted
between a low GPR56-associated signature and those related to epithelial differentiation and
cell proliferation. Hence, GPR56 is likely to function as a potential tumor-suppressor by
inhibiting the epithelial-mesenchymal transition (EMT) in certain cancer cells [57] (Table 2).
Table 2. The tumor-suppressive role of ADGRG1/GPR56.
Cancer Type Potential Mechanisms References
Melanoma
Binding of the ECM TG2 ligand inhibited tumor growth, angiogenesis, and
metastasis due to GPR56-mediated TG2 internalization and degradation, reduced




Inhibitory effects on cell adhesion and migration via Gαq-Rho signaling.
A restrictive role in mesenchymal differentiation and radioresistance due in part to
the inhibition of the NF-κB signaling pathway.
[45,57,81]
Taken together, GPR56 likely exerts tumor-suppressive functions in a tumor cell-type
specific manner via several signaling pathways including PKCα, Gαq-Rho, and NF-κB.
Interaction with TG2 seems to be a critical GPR56 activation mechanism in melanoma
cells, but its interacting ligand(s) in glioblastoma cells remains uncharacterized. Interest-
ingly, both melanoma and glioblastoma cells are mostly derived from the neuroepithelial
tissues originated from multipotent neural crest cells. The relationship between the tumor-
suppressive role of GPR56 and the common embryonic origin of tumor cells is an interesting
area of future research.
5. The Tumor-Promoting Role of ADGRG1/GPR56
Contrary to the tumor-suppressive functions discussed above, a potential tumor-
promoting/oncogenic function has been reported for GPR56 in diverse cancer types. There-
fore, in comparison to the surrounding normal tissues, upregulated GPR56 expression is
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detected in many human cancer tissues, including breast and pancreatic cancers, colorectal,
renal, cervical, esophageal squamous cell carcinoma (ESCC), non-small-cell lung carcinoma
(NSCLC), and epithelial ovarian tumors [80–82,90,96,97]. In general, upregulated GPR56
expression was associated with enhanced cell growth, adhesion, migration, and/or drug
resistance of cancer cells.
Ke et al. reported a positive correlation between higher GPR56 expression levels and
the transformation phenotypes of several cancer cell lines [81]. As such, GPR56-specific
gene silencing leads to enhanced apoptosis and reduced anchorage-independent growth of
cancer cells. By contrast, GPR56 overexpression in mouse fibroblast NIH3T3 cells promoted
cellular transformation and increased focus formation due to the loss of contact inhibition.
Finally, the tumorigenic role of GPR56 was analyzed in several in vivo models of tumor
xenograft using melanoma, colon, and prostate cancer cell lines. By inducing GPR56 gene
silencing at different stages of the in vivo tumor xenograft models and examining the final
tumor burdens, it was concluded that GPR56 plays a significant role in promoting tumor
growth at the early as well as advanced stages of tumor progression.
Similarly, forced GPR56 expression was found to promote the proliferation, migration,
and/or invasion of CRC, EOC, osteosarcoma, NSCLC, and prostate cancer cells by several
groups [80,82,90,96,98,99]. In contrast, GPR56 gene silencing resulted in increased cell
apoptosis and suppression of cell proliferation, migration, invasion, and/or tumor growth
of these cancer cells. Furthermore, Ji et al. demonstrated that GPR56 might enhance the
metastasis of CRC cells by promoting the EMT process via the induction of PI3K/AKT
signaling pathway [96]. Interestingly, concomitant expression of GPR56, TG2, and NF-κB
was detected in ESCCs, and a significant correlation was found between their expression
levels and the nodal invasion and metastasis of ESCCs [80,97]. As mentioned earlier,
our recent study in human melanoma cells showed that GPR56 activation induced IL-6
secretion, promoting cell migration and invasion via the Gα12/13-RhoA pathway [44]. In a
latest publication, Sasaki et al. showed that GPR56 played a crucial role in promoting bone
metastasis of breast cancer cells in a GPS proteolysis-dependent fashion by interacting with
collagen-III in metastasis sites [100].
The CSC subpopulation of CRC was marked specifically by the expression of Leucine-
rich repeat-containing G-protein coupled receptor 5 (LGR5) and LGR5+ CSCs cells were
able to transform to a more drug-resistant LGR5− phenotype. Zhang et al. identified
significantly increased GPR56 expression in drug-resistant LGR5− CRC cells compared
to LGR5+ CSCs. The GPR56+LGR5- CRC cells were more resistant to irinotecan and 5-
fluorouracil, likely due to the upregulated MDR1 expression induced by GPR56 via a
RhoA-dependent signaling mechanism [90]. Consistently, GPR56 knockdown reduced
MDR1 expression in CRCs leading to increased sensitivity to chemotherapy and impeded
tumor growth. In contrast, forced GPR56 overexpression in CRCs resulted in increased
tumor growth in vivo. Finally, the expression levels of GPR56 transcript were much higher
in primary colon tumors than in matched normal tissues and were correlated with poor
survival outcomes. Hence, GPR56 seems to be associated with the CSC plasticity and drug
resistance of colorectal tumors [90].
LSCs are the rare leukemia-initiating cells and represent the main driver for disease
relapse. As mentioned, GPR56 was identified as a stable LSC marker for the majority
of AML samples and that its expression was regulated in part by EVI1 in certain AML
cells [79,85]. Notably, EVI1-regulated GPR56 was associated with the enhanced cell adhe-
sion and antiapoptotic phenotypes observed in EVI1high human AML cells. Conversely,
GPR56 knockdown in AML cells resulted in increased cell migration and decreased cell
adhesion to a wide variety of ECM proteins via a RhoA-dependent signaling pathway.
In addition, strong Gpr56 expression was detected in murine HSCs and its expression
was gradually reduced during hematopoietic differentiation. Interestingly, the number of
HSCs was greatly reduced in the bone marrow (BM), but increased in the spleen, liver, and
peripheral blood of Gpr56-deficient mice, suggesting a role for Gpr56 in the maintenance
of HSCs in BM. Indeed, the in vivo repopulating ability of the Gpr56−/− HSCs was signifi-
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cantly impeded, likely due to their decreased cell adhesion and increased cell migration
abilities. Hence, Gpr56 might be involved in the BM retention and peripheral trafficking of
HSCs [79].
GPR56 expression in LSCs was higher than that in HSCs. Furthermore, a positive
correlation was established between a higher GPR56 expression level and the LSC gene
signature, as well as the high-risk AML patients and poor clinical outcomes [84,85]. Like-
wise, significantly high GPR56 expression was identified in AML cells of patients with
mutant nucleophosmin 1 (NPM1) and FMS-like tyrosine kinase 3 (FLT3)-length mutation.
Jentzsch et al. recently further showed a positive link between the high GPR56 expression
at diagnosis and a higher relapse risk of AML patients receiving allogeneic HSC transplan-
tation [101]. In summary, GPR56 expression seems to be closely associated with the disease
progression of myeloid leukemia.
The functional role of GPR56 in myeloid leukemogenesis was validated using murine
hematopoietic progenitor cells (HPCs) co-expressing homeobox A9 (HOXA9) and Gpr56,
which increased primary colony formation in vitro and accelerated myeloid leukemoge-
nesis in vivo compared to HPCs expressing HOXA9 alone [84]. Conversely, the develop-
ment of leukemia in vivo was greatly delayed in mice transplanted with HOXA9/Meis1-
transduced cells in which the Gpr56 expression was knock-downed by gene-specific
shRNAs. Importantly, leukemic engraftment of the NOD scid gamma (NSG) mice by
the HOXA9-expressing MV4-11 AML cell line was impaired significantly following the
functional blockage of GPR56 by an anti-GPR56 mAb. Taken together, these findings
demonstrate clearly that GPR56 contributes positively to AML development and identify
GPR56 as a potential Ab-based therapeutic target in AML (Table 3).
Table 3. The tumor-promoting role of ADGRG1/GPR56.
Cancer Type Potential Mechanisms References
Breast, pancreatic, cervical, ovarian,
prostate, and colorectal cancers,
non-small-cell lung carcinoma (NSCLC),
and esophageal squamous cell carcinoma
Upregulated GPR56 expression in cancer cells promoted cell




GPR56 promoted the EMT process via the induction of
PI3K/AKT signaling pathway.
GPR56 upregulated MDR1 expression via a
RhoA-dependent signaling pathway.
[90,96]
Melanoma GPR56 activation upregulated IL-6 production, promotingcell migration [44]
Acute myeloid leukemia (AML)
GPR56 enhanced cell adhesion and antiapoptotic functions
a RhoA-dependent signaling pathway.
Gpr56+ HPCs increased primary colony formation in vitro
and accelerated myeloid leukemogenesis in vivo.
[79,84,85]
In summary, GPR56 is upregulated in many cancer types and functions as a potential
tumor-promoting receptor, modulating cell growth, apoptosis, migration/invasion, EMT
process, and/or drug resistance. The upregulated GPR56 expression in cancer is cell type-
specific and is regulated in part by unique transcription factors such as EVI1. Several
signaling pathways such as the PI3K/AKT and Gα12/13-RhoA axes are implicated in
its tumor-promoting functions; however, the cellular ligand(s) and the exact receptor
activation mechanisms involved require further studies. In contrast to the neural crest
origin of melanoma and glioblastoma, the origins of these carcinoma and LSC/HPC cells
are of epithelial and hematopoietic lineages, respectively. It is hence possible that the
tumor-promoting or tumor-suppressive functions of GPR56 is determined in part by the
differential signaling responses of tumor cells of different origins.
Cells 2021, 10, 3352 11 of 16
6. Unmet Challenges
While the roles of GPR56 in tumor development have been increasingly recognized,
more detailed investigation is required in several areas of research. As elucidated pre-
viously, earlier studies have not addressed the possible involvement of diverse GPR56
transcripts and receptor isoforms nor the signaling pathways in tumor progression. Consid-
ering the extensive GPR56 RNA splicing and exon usage, many potential GPR56 variants
with different ligand-binding and signaling functions could be expressed in tumor cells.
Hence, it will be of importance to know if some unique receptor RNA transcripts and iso-
forms such as the smaller 1st intracellular loop-containing GPR56-S1 and the PLL-truncated
GPR56-S4 variants are expressed in more abundance in certain cancer types. The use of
single-cell RNA sequencing analysis perhaps will help answer this question and pave
the way for the understanding of whether alternative splicing of GPR56 modulate its
tumorigenic functions. These studies might be extended to explore whether certain splice
variants could predict and therefore be used to diagnose tumor outcomes better than the
full-length GPR56. In view of the close association of disease-causing GPR56 mutations
with BFPP, the impact of GPR56 mutations in tumorigenesis will be an important direction
for future investigation.
Similarly, the role of GPR56-specific cellular ligands in different tumors has not been
delineated in detail. The results of several studies have shown that GPR56-TG2 interaction
impeded melanoma growth, angiogenesis and metastasis, whereas GPR56 binding to
collagen-III promoted the metastasis of breast cancer cells to bone [31–33,100]. Thus, the
interaction of GPR56 and its specific ligands clearly plays a critical role in the functional
modulation of tumor cells and therefore needs deeper investigation. Most current studies
relied heavily on the levels of GPR56 transcripts in solid tumor samples with minimum
data of GPR56 protein expression. Moreover, the overall evaluation of the quality of protein
expression studies in human cancer samples is not applicable because of the use of different
reagents such as monoclonal and polyclonal Abs by different researchers. Indeed, anti-
GPR56 Abs used in various solid tumor studies were polyclonal Abs developed in different
animal species such as rabbit, mouse, goat, and sheep [82,83,89,98]. The Ag fragments used
for Ab generation included different lengths of GPR56-ECR peptides as well as the full-
length GPR56 protein expressed in transfected cells. In addition, the quantitative analyses
of GPR56 expression in solid tumors as revealed by immunohistochemical analysis required
careful evaluation of the different stages of cancer samples, the experimental procedures of
tissue section preparation, as well as Ag retrieval and Ab staining conditions. It is hence
difficult to compare GPR56 protein expression data in a systematic and comprehensive
fashion among different published results. For example, in the study of the potential tumor-
suppressor role of GPR56 in GBM, goat-derived GPR56 polyclonal Abs were used mainly
in western blotting analyses with only one immunohistochemical staining result [57].
By contrast, mouse anti-GPR56 polyclonal Abs were employed exclusively in western
blotting analyses of CRC cell lines to examine its possible tumor-promoting role [90]. No
immunohistochemical analysis of GPR56 expression was investigated in this study. It is
therefore essential to develop robust Ab reagents in the future for the detection of GPR56
receptor isoforms in situ.
GPS auto-proteolysis is a unique post-translational modification important for certain
functional aspects of aGPCRs. As discussed, GPS cleavage-dependent and -independent
functions have been described for GPR56. Nevertheless, the involvement of GPS auto-
proteolysis in the tumorigenic role of GPR56 has not yet been studied fully. In addition, the
possible role of GPR56 cis-interacting proteins such as CD9 and CD81 in modulating the
tumorigenic functions of GPR56 also requires further attention. Finally, there are very few
studies focusing on the regulation of GPR56 expression by specific transcription factors in
cancers. Answers to these questions will not only delineate the regulatory mechanisms of
GPR56′s functions in tumorigenesis but also help reveal the paradoxical tumor-promoting
and tumor-suppressive roles of GPR56 in different cancer types.
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7. Conclusions and Future Perspective
ADGRG1/GPR56 is undoubtedly an important aGPCR relevant in tumor develop-
ment. However, its role in tumorigenesis seems to depend critically on tumor cell type-
and/or stage-specific contexts. This conclusion is not only backed up by the divergent
results from multiple human cancer types discussed above, but also from animal tu-
mor models of endogenous cancer progression [102,103]. As such, the development of
GPR56-specific agonists and antagonists will be needed for the deeper understanding of its
functional role in different cancer types. In addition, the development of specific reagents
such as the pyrrole-imidazole polyamides that disrupted the binding of EVI-1 to the GPR56
promoter is an alternative therapeutic approach to modulate GPR56 expression in certain
cancer types [104]. Future studies also need to dissect further the exact signaling pathways
and the ligands/interacting partners of GPR56 at specific stages of tumor development
in order to identify the molecular targets of which therapeutic intervention can be de-
vised. Nevertheless, with the realization of it being a specific surface marker of unique
cancer cell types such as the LSC of AML, GPR56 may be an ideal molecular target for the
combinatorial chimeric antigen receptor (CAR) therapy against AML [105].
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